TY - JOUR
T1 - Oncolytic virotherapy – Forging its place in the immunomodulatory paradigm for Multiple Myeloma
AU - Cook, Joselle
AU - Acosta-Medina, Aldo A.
AU - Peng, Kah Whye
AU - Lacy, Martha
AU - Russell, Stephen
N1 - Publisher Copyright:
© 2021
PY - 2021/1
Y1 - 2021/1
N2 - The treatment focus for multiple myeloma (MM) has recently pivoted towards immune modulating strategies, with T-cell redirection therapies currently at the forefront of drug development. Yet, despite this revolution in treatment, MM remains without a sustainable cure. At the same time, tremendous advancement has been made in recombinant and gene editing techniques for oncolytic viruses (OV), which have increased their tumor specificity, improved safety, and enhanced the oncolytic and immunostimulatory potential. These breakthrough developments in oncolytic virotherapy have opened new avenues for OVs to be used in combination with other immune-based therapies such as checkpoint inhibitors, chimeric antigen receptor T-cells (CAR-T) and bispecific T-cell engagers. In this review, the authors place the spotlight on systemic oncolytic virotherapy as an adaptable immunotherapeutic for MM, highlight the unique mechanism of OVs in activating the immune-suppressive marrow microenvironment, and lastly showcase the OV platforms and the promising combination strategies in the pipeline for MM.
AB - The treatment focus for multiple myeloma (MM) has recently pivoted towards immune modulating strategies, with T-cell redirection therapies currently at the forefront of drug development. Yet, despite this revolution in treatment, MM remains without a sustainable cure. At the same time, tremendous advancement has been made in recombinant and gene editing techniques for oncolytic viruses (OV), which have increased their tumor specificity, improved safety, and enhanced the oncolytic and immunostimulatory potential. These breakthrough developments in oncolytic virotherapy have opened new avenues for OVs to be used in combination with other immune-based therapies such as checkpoint inhibitors, chimeric antigen receptor T-cells (CAR-T) and bispecific T-cell engagers. In this review, the authors place the spotlight on systemic oncolytic virotherapy as an adaptable immunotherapeutic for MM, highlight the unique mechanism of OVs in activating the immune-suppressive marrow microenvironment, and lastly showcase the OV platforms and the promising combination strategies in the pipeline for MM.
KW - Immunomodulation
KW - Multiple Myeloma
KW - Oncolytic virus
KW - Virotherapy
UR - http://www.scopus.com/inward/record.url?scp=85122841196&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122841196&partnerID=8YFLogxK
U2 - 10.1016/j.ctarc.2021.100473
DO - 10.1016/j.ctarc.2021.100473
M3 - Article
C2 - 34673439
AN - SCOPUS:85122841196
SN - 2213-0896
VL - 29
JO - Cancer Treatment and Research Communications
JF - Cancer Treatment and Research Communications
M1 - 100473
ER -